Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study

Antoine Bessou, Xavier Colin, Julie De Nascimento, Will Sopwith, Shannon Ferrante, Boris Gorsh, Benjamin Gutierrez, Leah Sansbury, Jenny Willson, Sandhya Sapra, Prani Paka and Feng Wang ()
Additional contact information
Antoine Bessou: IQVIA
Xavier Colin: GlaxoSmithKline
Julie De Nascimento: IQVIA
Will Sopwith: IQVIA
Shannon Ferrante: Value Evidence and Outcomes, GlaxoSmithKline
Boris Gorsh: Value Evidence and Outcomes, GlaxoSmithKline
Benjamin Gutierrez: Value Evidence and Outcomes, GlaxoSmithKline
Leah Sansbury: Value Evidence and Outcomes, GlaxoSmithKline
Jenny Willson: Value Evidence and Outcomes, GlaxoSmithKline
Sandhya Sapra: Value Evidence and Outcomes, GlaxoSmithKline
Prani Paka: Global Medical Affairs, GlaxoSmithKline
Feng Wang: Value Evidence and Outcomes, GlaxoSmithKline

The European Journal of Health Economics, 2023, vol. 24, issue 3, No 1, 333 pages

Abstract: Abstract Background Real-world data on health care resource utilisation (HCRU) and costs for French patients with multiple myeloma (MM) are limited due to the quickly evolving MM treatment landscape. This retrospective, national-level study quantified the MM economic burden in France. Methods The study included patients with newly diagnosed MM from the Système National des Données de Santé coverage claims database between 2013 and 2018 who received active treatment within 30 days of diagnosis. HCRU included hospitalisations, drugs, consultations, procedures, tests, devices, transport, and sick leave. Costs were annualized to 2019 prices. Drug treatments, reported by line of therapy (LOT), were algorithmically defined using drug regimen, duration of therapy, and gaps between treatments. Analyses were stratified by stem cell transplantation status and LOT. Results Among 6413 eligible patients, 6229 (97.1%) received ≥ 1 identifiable LOT; most received 1 (39.8%) or 2 LOT (27.5%) during follow-up. Average annual hospitalisation was 6.3 episodes/patient/year (median duration: 11.6 days). The average annual cost/patient was €58.3 K. Key cost drivers were treatment (€28.2 K; 39.5% of total HCRU within one year of MM diagnosis) and hospitalisations (€22.2 K; 48.6% of total HCRU costs in first year). Monthly treatment-related costs increased from LOT1 (€2.447 K) and LOT5 + (€7.026 K); only 9% of patients received LOT5 + . At LOT4 + , 37 distinct regimens were identified. Hospitalisation costs were higher in patients with stem cell transplantation than total population, particularly in the first year. Conclusions This study showed a high economic burden of MM in France (€72.37 K/patient/year in the first year) and the diversity of regimens used in late-line treatments.

Keywords: Multiple myeloma; HCRU; Cost; Line of therapy; Economic burden; France (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-022-01463-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:24:y:2023:i:3:d:10.1007_s10198-022-01463-9

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-022-01463-9

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().